Table 4.
Other factors involved in drug availability.
| Reference | Population | Treatment | Diagnosis | Response criteria | Follow-up | Predictor | Risk of bias |
|---|---|---|---|---|---|---|---|
| Ma et al. (2019) | 174 AD patients (with patients treated with R as a control group) | Donepezil, galantamine, rivastigmine | Clinical (probable and possible AD, NINCDS-ADRDA) | No deterioration in ADAS-Cog and MMSE | 1 year | CYP3A4*1G carriers have poorer responses (especially if CYP2D6 non-carriers) | High |
| Magliulo et al. (2011) | 54 AD patients | Donepezil | Clinical (probable AD, NINCDS-ADRDA) | Not clearly stated (change in CIBIC-plus or in MMSE) | Up to 40 months (median 9 months) | CYP3A4 and CYP3A5 are not a predictor | High |
| Rozzini et al. (2008) | 110 AD patients (98 completed the study) | Donepezil | Clinical (probable AD, NINCDS-ADRDA) | Change in ADAS-Cog (not clearly stated) | 15 months | Albumin <4 g/dl (for donepezil) | High |
| Ortner et al. (2020) | 48 AD patients on D, 28 AD patients on R | Donepezil, rivastigmine | Clinical (AD, NIAA) | Change in CERAD-NAB subtests and total score | Not stated, mean 5.7 ± 2.53 months for D and 5.59 ± 2.09 months for R | Higher rivastigmine concentration; donepezil concentrations are not a predictor | Low |
| Chen et al. (2017) | 63 AD patients | Rivastigmine | Clinical (NINCDS-ADRDA, not stated if probable or possible) | Improvement in either MMSE or CDR | 6 months | Rivastigmine concentration | Moderate |
| Yang et al. (2013) | 37 AD patients | Donepezil 5 mg | Clinical (NINCDS-ADRDA, not stated if possible included) | No deterioration in total and subscales of CASI scores | 6 months | Higher donepezil plasma concentration (for long-term memory response) | Moderate |
| Lu et al. (2015) | 77 AD patients | Donepezil | Not stated | No deterioration in MMSE | At least 3 months | Higher concentration of S-Donepezil (in patients with CYP2D6*10/10 on rs1065852 SNP) | High |
| Lin et al. (2019) | 33 AD patients | Galantamine 8 mg | Clinical (NINCDS-ADRDA, not stated if possible included) | No deterioration in MMSE, CASI, and CDR-SB (doesn't state if only one is needed) | 6 months | Galantamine plasma concentration is not a predictor | Low |
| Miranda et al. (2017) | 42 AD and AD+CVD patients | Donepezil | Clinical (AD, NIAA; AD+CVD, NINDS-AIREN) | Less than 1 point loss on MMSE | 12 months | Donepezil concentration is not a predictor | Low |
| Wattmo et al. (2018) | 1,017 AD patients | Donepezil, galantamine, rivastigmine | Clinical (possible or probable AD, NINCDS-ADRDA, and DSM-IV) | No deterioration in MMSE | 3 years | Higher mean dose of ChEI | High |
| Wattmo et al. (2011) | 843 AD patients | Donepezil, galantamine, rivastigmine | Clinical (possible or probable AD, NINCDS-ADRDA, and DSM-IV) | Not clearly stated, changes in MMSE and ADAS-Cog | 3 years | Higher mean does of ChEI | High |
| Wattmo et al. (2012) | 784 AD patients | Donepezil, galantamine, rivastigmine | Clinical (possible or probable AD, NINCDS-ADRDA, and DSM-IV) | No deterioration in IADL or PSMS at 6 months | 3 years | Higher mean does of ChEI | High |
| Farlow et al. (2015) | 716 severe AD patients (628 included) | Rivastigmine 13.3/4.6 mg | Clinical (probable AD, NINCDS-ADRDA) | Improvement/improvement or no change on ADCS-CGIC | 24 weeks | Treatment with 13.3 mg/24 h rivastigmine patch | Some concerns—Low |
| Molinuevo et al. (2015) | 536 AD patients (ITT analysis) | Rivastigmine | Clinical (probable AD, NINCDS-ADRDA) | Improvement of 4+ points on ADAS-Cog, with no decline on ADCS-IADL | 48 weeks | Treatment with 13.3 mg/24 h rivastigmine patch | Some concerns—Low |
| Touchon et al. (2006) | 994 AD patients (ITT-LOCF) | Donepezil, rivastigmine | Clinical (probable AD, NINCDS-ADRDA, and DSM-IV; DLB with McKeith or concurrent use of anti-parkinsonian medication) | Change in Severe Impairment Battery, GDS, ADCSL-ADL, MMSE, NPI | 104 weeks | No predictors | Some concerns—Low |